BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
October 17, 2024 08:07 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
Immunology Collaboration and Licensing Agreements Trends Report 2024: Explore 862 Detailed Contract Documents via SEC Submissions - Access Deal Payment Terms and Trigger Clauses
October 14, 2024 06:46 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
October 11, 2024 06:00 ET
|
Turnstone Biologics Corp.
Turnstone Biologics announces strategic restructuring to prioritize portfolio and extend financial runway.
Immatics Announces Pricing of $150 Million Public Offering
October 10, 2024 20:50 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Proposed $150 Million Public Offering
October 10, 2024 07:30 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
October 10, 2024 06:30 ET
|
https://immatics.com/
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily...
Cancer Immunotherapy Market Research 2024-2032: Personalized Cancer Vaccines and CAR T Cell Therapy Revolutionize Immunotherapy
October 07, 2024 07:18 ET
|
Research and Markets
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report, Forecast by Products, Application, End Users, Countries and Company Analysis, 2024-2032" report has been added to ...
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
October 04, 2024 10:31 ET
|
Compass Therapeutics
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
October 04, 2024 09:00 ET
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
October 01, 2024 08:00 ET
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.